Omzotirome (INN), formerly codenamed TRC-150094, is a thyromimetic drug which acts as a metabolic modulator which restores metabolic flexibility.

It has been shown to improve insulin resistance and hyperglycemia, and is in Phase III human clinical trials for the treatment of Cardiometabolic-Based Chronic Disease (CMBCD) by improving dysglycemia, dyslipidemia and hypertension.

[1][2][3][4][5]

This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.